FDA strengthens monitoring of post-approval drug safety

23 April 2012

In what is seen as a response to criticism that the agency lacks teeth in monitoring drugs once they are approved for marketing, the US Food and Drug Administration on Saturday released a report from its Center for Drug Evaluation and Research (CDER) aimed at strengthening and modernizing post-market drug safety oversight.

The report, titled Advances in FDA’s Safety Program for Marketed Drugs, describes new scientific tools and enhanced capabilities that give the same priority to post-market drug safety monitoring as to premarket drug review.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Biotechnology